Cargando…
Therapeutic Options for Patients who are not Eligible for Intensive Chemotherapy
Although “less intense” therapies are finding more use in AML, the principal problem in AML remains lack of efficacy rather than toxicity. Hence less intense therapies are of little use if they are not more effective as well as less toxic than standard therapies. Assignment of patients to less inten...
Autor principal: | Estey, Elihu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736881/ https://www.ncbi.nlm.nih.gov/pubmed/23936621 http://dx.doi.org/10.4084/MJHID.2013.050 |
Ejemplares similares
-
Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility
por: Percival, Mary-Elizabeth M., et al.
Publicado: (2020) -
Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal
por: Estey, Elihu, et al.
Publicado: (2022) -
Patterns of undertreatment among patients with acute myeloid leukemia (AML): considerations for patients eligible for non-intensive chemotherapy (NIC)
por: Hubscher, Elizabeth, et al.
Publicado: (2021) -
Understanding the Pathogenesis of Cardiac Complications in Patients with Propionic Acidemia and Exploring Therapeutic Alternatives for Those Who Are Not Eligible or Are Waiting for Liver Transplantation
por: Maines, Evelina, et al.
Publicado: (2023) -
End-of-Life Care of Acute Myeloid Leukemia Compared with Aggressive lymphoma in Patients Who Are Eligible for Intensive Chemotherapy: An Observational Study in a Japanese Community Hospital
por: Kokaji, Masato, et al.
Publicado: (2023)